TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET ANALYSIS

Regional Analysis

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Regional Analysis

North America is expected to hold the dominant position in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market over the forecast period, owing to increasing development and launches of new products in the region. For instance, under a global biosimilars development and commercialization agreement between Merck and Samsung Bioepis Co., Ltd., Renflexis (biosimilar of Remicade (infliximab)) received the U.S. FDA approval in 2019 and was the first medicine to be available in the U.S. as a TNF inhibitor.

Moreover, Amgen Inc. also announced the U.S. FDA approval for avsola in 2019 (infliximab-axxq) for all approved indications of the reference product, Remicade (infliximab) in the U.S. Also, Celgene Corporation recently received the U.S. FDA approval for otezla (apremilast) in 2019, an oral PDE4 inhibitor for the treatment of adult patients with mucositis (mouth ulcers) associated with behçet’s disease, a rare disorder that causes blood vessel inflammation throughout the body. Otezla is the first drug to be approved for this use in the U.S., providing a treatment option for behçet’s disease, many of whom develop mouth ulcers as a result of the condition.

Increasing incidence of autoimmune diseases in the population is expected to be another factor supporting the growth of North America in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2017, around 54.4 million adults in the U.S. were suffering from arthritis, which equals about 25% of the total population while, around 1.3 million people, 294,000 people and 0.6 to 2.4 million people over 15 years of age in the U.S were suffering from rheumatoid arthritis, juvenile arthritis, and spondylarthritides, respectively.

According to the same source, by the year 2040, it is estimated that 78 million (26%) of the U.S. adults in the age range of 18 years or older are expected to have arthritis. Therefore increasing prevalence of autoimmune diseases in North America is expected to boost the tumor necrosis factor drugs inhibitor market growth over the forecast period.